<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR16">
 <label>16.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Reck</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>von Pawel</surname>
    <given-names>J</given-names>
   </name>
   <name>
    <surname>Zatloukal</surname>
    <given-names>P</given-names>
   </name>
   <name>
    <surname>Ramlau</surname>
    <given-names>R</given-names>
   </name>
   <name>
    <surname>Gorbounova</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Hirsh</surname>
    <given-names>V</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)</article-title>
  <source>Ann Oncol</source>
  <year>2010</year>
  <volume>21</volume>
  <fpage>1804</fpage>
  <lpage>1809</lpage>
  <pub-id pub-id-type="doi">10.1093/annonc/mdq020</pub-id>
  <?supplied-pmid 20150572?>
  <pub-id pub-id-type="pmid">20150572</pub-id>
 </element-citation>
</ref>
